The recent decision by the Federal Circuit introduces a noteworthy stipulation wherein patents, in order to be included in the Orange Book—a publication by the U.S. Food and Drug Administration—must explicitly claim a drug’s active ingredient. This ruling raises questions concerning the listing of numerous patents, potentially leading to the improper inclusion of some. The future of these patents and how the ruling will affect generic drug competition remains uncertain. Legal professionals are closely monitoring the implications of this decision. For further details, more information is available in the Law360 article.